sivelestat has been researched along with Cancer of Liver in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hanazaki, K; Kobayashi, M; Okabayashi, T; Shiga, M; Sugimoto, T; Takezaki, Y; Tsujii, S | 1 |
| Akamoto, S; Izuishi, K; Okano, K; Sano, T; Suzuki, Y; Usuki, H; Wakabayashi, H; Yachida, S | 1 |
2 trial(s) available for sivelestat and Cancer of Liver
| Article | Year |
|---|---|
The effect of the neutrophil elastase inhibitor sivelestat on early injury after liver resection.
Topics: Aged; Biomarkers; Drug Administration Schedule; Female; Glycine; Hepatectomy; HMGB1 Protein; Humans; Interleukin-6; Leukocyte Elastase; Liver; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Reperfusion Injury; Serine Proteinase Inhibitors; Sulfonamides; Treatment Outcome | 2012 |
Neutrophil elastase inhibitor (sivelestat) preserves antitumor immunity and reduces the inflammatory mediators associated with major surgery.
Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Digestive System Neoplasms; Digestive System Surgical Procedures; Esophageal Neoplasms; Esophagectomy; Female; Glycine; Humans; Interleukin-6; Leukocyte Elastase; Liver Neoplasms; Male; Middle Aged; Pancreaticoduodenectomy; Postoperative Period; Prospective Studies; Serine Proteinase Inhibitors; Single-Blind Method; Stress, Physiological; Sulfonamides; Th1 Cells; Th2 Cells | 2007 |